Comparative Pharmacology
Head-to-head clinical analysis: METHADONE MOUD versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADONE MOUD versus QDOLO.
Methadone (MOUD) vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist with high affinity. It also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and maintenance effects.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Initial: 20-30 mg orally once daily, titrated to effect. Maintenance: 10-120 mg orally once daily. Route: oral (tablet, liquid). Frequency: once daily.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours following single dose; 13-50 hours with chronic dosing (due to tissue redistribution). Context: prolonged half-life supports once-daily dosing for opioid use disorder but requires careful titration to avoid accumulation.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal (20-40% as unchanged drug, with urine pH-dependent elimination; 50% as metabolites including EDDP and EMDP). Biliary/fecal excretion accounts for approximately 10-15%.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category A/B
Category C
Opioid Agonist
Opioid Agonist